ASTRAZENECA PHARMACEUTICALS LP for ASTRAZENECA PHARMACEUTICALS LP
What was lobbied
9 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
HR 3521/ S 4440 Clinical Trial Modernization Act HR 946/S 1862 Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act Discuss Vaccine concerns Cell Therapy Broad discussion on drug pricing CMMI GENEROUS Demo FDA modernization policy 340B policy Demo for CMMI regarding copay caps Policies related to international reference pricing for pharmaceuticals Issues related to pharmacy benefit manager (PBM) reform Issues related to mitigation of 340B Issues and policies related to 340B Rebate Model Pilot Program for IRA compliance Issues related to most-favored nations drug pricing proposals Issues related to implementation and/or expansion of the Inflation Reduction Act (IRA) Issues related to the price and manufacture of inhaled medicines Issues related to next generation propellant and PFAS Issues related to vaccine access and vaccine R&D, including ACIP recommendations Issues related to the development of novel therapies including cell therapy and antibody drug conjugates (ADCs) Issues related to the recruitment of patients for clinical trials clinical trial modernization act
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATIE JONES | — |
| EMILY MACE | — |
| BAILEY LAUREN MCCUE | — |
| TALEEN MEKHDJAVAKIAN | — |
| CAROLINE QUAT | — |
Labor Issues/Antitrust/Workplace LBR
Job growth related to US manufacturing investments workforce incentives (non-tax, related to grants and support for apprenticeship programs)
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATIE JONES | — |
Medicare/Medicaid MMM
HR 7118 Genomic Answers for Children's Health Act HR 9599 The SECURE 340B Act Policies related to the use of international reference pricing in Medicare/Medicaid 340B rebate model Issues related to Part B and Part D drug access Medicare drug price negotiation Medicare patient access to cancer screening Medicare patient access to rare disease therapies Efforts to improve coding, coverage, and access for rare disease therapies Issues related to e-labeling and allowing FDA to finalize a rule to allow digital versions of prescriptions Issues related to a Most Favored Nations policy in Medicare and Medicaid Most Favored Nation drug pricing proposals Issues related to the digital communication of prescribing information for drugs
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATIE JONES | — |
| LISA LANGENDERFER | — |
| EMILY MACE | — |
| CAROLINE QUAT | — |
Pharmacy PHA
HR 4132/S 2027, Prescription Information Modernization Act; E-labeling (allowing health care providers to receive prescribing information for drugs electronically rather than in paper form from manufacturers) Issues related to increasing production of US manufacturing
| Lobbyist | Covered position, as disclosed |
|---|---|
| CAROLINE QUAT | — |
Copyright/Patent/Trademark CPT
AZ Inhaler Patent issue raised at Energy and Commerce hearing Issues related to patents and intellectual property information on patent extension and effect on pharmacy drug costs
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATIE JONES | — |
| TALEEN MEKHDJAVAKIAN | — |
| CAROLINE QUAT | — |
Trade (domestic/foreign) TRD
US trade tools (investigations, tariffs, trade agreements, congressional oversight, rules of origin, CBP enforcement, investment screening) US-Mexico-Canada trade agreement (USMCA) US-China trade Most Favored Nations and pharmaceutical R&D innovation Pharmaceutical supply chain resilience
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATIE JONES | — |
Taxation/Internal Revenue Code TAX
HR 1414 - Camerons Law, to restore orphan drug research tax credit HR 1990 - American Innovation and R&D Competitiveness Act of 2025 S 1605 - International Competition for American Jobs Act S 3841 - Last Sale Valuation Act of 2026 Most Favored Nations and pharmaceutical R&D innovation Tax incentives for manufacturing workforce development Tax proposals building on One Big Beautiful Bill Act law and implementation (R&D expensing, BEAT, FDII, Corporate Alternative Minimum Tax)
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA LANGENDERFER | — |
Insurance INS
Issues related to PBM policies and PBM legislation Issues related to implementation and/or expansion of Inflation Reduction Act, including formulary issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| CAROLINE QUAT | — |
Manufacturing MAN
Pharmaceutical supply chain US investments
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATIE JONES | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.